Novo Nordisk: Already 2 million prescriptions for the Wegovy pill. Strong start to the year boosts the stock!

The Danish pharmaceutical company Novo Nordisk has reported strong figures for the first quarter of 2026 and raised its outlook for the full year. The main driver of this development is the high demand for the recently introduced Wegovy pill, with already 2 million prescriptions since its launch. For the full year 2026, Novo Nordisk now expects an adjusted revenue growth of -4% to -12% at constant exchange rates, which represents an increase from the previous forecast of -5% to -13%. The outlook for the adjusted operating profit has also been raised...